FERRO, Stefania
 Distribuzione geografica
Continente #
NA - Nord America 10.950
EU - Europa 8.280
AS - Asia 3.985
SA - Sud America 1.440
AF - Africa 137
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 24.804
Nazione #
US - Stati Uniti d'America 10.798
RU - Federazione Russa 4.368
SG - Singapore 1.642
BR - Brasile 1.250
CN - Cina 1.116
IE - Irlanda 1.012
SE - Svezia 870
HK - Hong Kong 425
UA - Ucraina 394
IT - Italia 386
DE - Germania 335
VN - Vietnam 335
FR - Francia 255
GB - Regno Unito 215
FI - Finlandia 214
IN - India 143
AR - Argentina 76
CA - Canada 67
MX - Messico 57
CZ - Repubblica Ceca 43
IQ - Iraq 41
BE - Belgio 38
BD - Bangladesh 37
TR - Turchia 37
ZA - Sudafrica 37
PL - Polonia 36
EC - Ecuador 31
JP - Giappone 29
MA - Marocco 29
CI - Costa d'Avorio 23
UZ - Uzbekistan 22
CO - Colombia 21
NL - Olanda 21
ID - Indonesia 20
ES - Italia 18
AT - Austria 17
PK - Pakistan 16
VE - Venezuela 14
PY - Paraguay 13
SA - Arabia Saudita 13
EG - Egitto 12
KE - Kenya 11
AE - Emirati Arabi Uniti 9
CL - Cile 9
PE - Perù 9
UY - Uruguay 9
JO - Giordania 8
KG - Kirghizistan 8
OM - Oman 8
PH - Filippine 8
BO - Bolivia 7
DO - Repubblica Dominicana 7
NP - Nepal 7
AZ - Azerbaigian 6
CH - Svizzera 6
KR - Corea 6
LV - Lettonia 6
GR - Grecia 5
IR - Iran 5
KZ - Kazakistan 5
LK - Sri Lanka 5
MY - Malesia 5
TN - Tunisia 5
AL - Albania 4
CR - Costa Rica 4
IL - Israele 4
JM - Giamaica 4
MD - Moldavia 4
NO - Norvegia 4
PA - Panama 4
RO - Romania 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
GT - Guatemala 3
HU - Ungheria 3
LB - Libano 3
LT - Lituania 3
LU - Lussemburgo 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
TW - Taiwan 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CG - Congo 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
NG - Nigeria 2
RS - Serbia 2
TH - Thailandia 2
BN - Brunei Darussalam 1
Totale 24.786
Città #
Dallas 5.019
Moscow 1.229
Dublin 1.010
Singapore 843
Jacksonville 780
Ashburn 769
Chandler 726
Nyköping 577
Beijing 442
Hong Kong 424
The Dalles 230
Princeton 179
Dearborn 170
Los Angeles 168
Cambridge 167
Medford 160
Lauterbourg 157
San Jose 157
Des Moines 133
Ann Arbor 127
Messina 123
Dong Ket 116
Boardman 106
São Paulo 87
Ho Chi Minh City 77
Buffalo 72
New York 61
Lancaster 60
Wilmington 48
Woodbridge 48
Guangzhou 45
Tianjin 45
Hyderabad 41
Jinan 41
Orem 41
San Mateo 40
Pune 38
Redondo Beach 37
Brussels 36
Munich 36
Hanoi 35
Belo Horizonte 34
Shenyang 34
Denver 31
Brasília 30
Brno 30
Frankfurt am Main 30
Catania 29
Rio de Janeiro 29
Nanjing 28
Brooklyn 27
Phoenix 26
Tokyo 25
Johannesburg 24
Abidjan 23
Turku 23
Lappeenranta 22
Santa Clara 22
Tashkent 22
Warsaw 22
Baghdad 21
Atlanta 20
Chicago 20
Düsseldorf 20
Haikou 20
Hebei 20
Houston 20
Montreal 20
London 19
Seattle 19
Porto Alegre 17
Shanghai 17
Hangzhou 16
Goiânia 15
Manchester 15
Ningbo 15
Zhengzhou 15
Chennai 14
Guarulhos 14
Mexico City 14
Mumbai 14
Stockholm 14
Taizhou 14
Vienna 14
Curitiba 13
Da Nang 13
Guayaquil 13
Milan 13
Ottawa 13
Biên Hòa 12
Boston 12
Campinas 12
Fuzhou 12
Quito 12
Contagem 11
Haiphong 11
Poplar 11
Ribeirão Preto 11
San Francisco 11
Amsterdam 10
Totale 15.808
Nome #
1,3-diidro-benzimidazoloni analoghi: progettazione, sintesi e SAR di nuovi inibitori non-nucleosidici dell'RT 4.608
1-Aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamide derivatives: synthesis and biological evaluation 268
Chemical exploration of 4-(4-fluorobenzyl)piperidine fragment for the development of new tyrosinase inhibitors 253
Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases 202
AMPA receptor antagonists: Synthesis and pharmacological evaluation 201
Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments 194
4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. 187
Exploring structural properties of potent human carbonic anhydrase inhibitors bearing a 4-(cycloalkylamino-1-carbonyl)benzenesulfonamide moiety 184
Identification of Potent and Selective Human Carbonic Anhydrase VII (hCA VII) Inhibitors 181
InVivo Evaluation of Selective Carbonic Anhydrase Inhibitors as Potential Anticonvulsant Agents 181
3D Pharmacophore model and synthesys of NMDA receptor subunit NR2B antagonists 178
A New 3D Pharmacophore Model for HIV-1 Integrase Strand Transfer Inhibitors. 178
A structure-based approach to ligand discovery for inhibition of HIV-1 IN-LEDGF/p75 interaction: a new target for anti-AIDS therapy 178
Design and optimization of isoquinoline-sulfonamides as potent and selective inhibitors of human carbonic anhydrase VII 177
Carbonic anhydrase inhibitors: Design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms 177
Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8ΔCTE inhibitors as potential therapeutics for leishmaniasis 177
A New 3D Pharmacophore Model for HIV-1 Integrase Strand Transfer Inhibitors 175
A refined pharmacophore model and optimization of 1H-benzylindole HIV-1 integrase inhibitors 170
A new potential approach to block HIV-1 replication via protein–protein interaction and strand-transfer inhibition 170
HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation 164
Antiretroviral strategy using multi-target agents 162
From 3D-pharmacophore models to synthetic route towards anti-HIV agents 161
DISCOVERY OF NEW INDOLE DERIVATES AS NEUROPROTECTIVE AGENTS 161
Discovery of potent and selective inhibitors of druggable carbonic anhydrase isoforms 160
Microwave-assisted synthesis of benzimidazole and thiazolidinone derivatives as HIV-1 RT inhibitors 159
Combined ligand-based and target-based approach to design NR2B/NMDA receptor antagonists 159
Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. 159
Identification of isoquinoline-sulfonamides as potent and selective carbonic anhydrase inhibitors 159
Modificazioni strutturali del gruppo dichetoacido (DKA) di potenti inibitori dell'Integrasi dell'HIV-1 158
Inhibitors of the Interactions between HIV-1 IN and the Cofactor LEDGF/p75 158
Graphene Quantum Dots Based Systems As HIV Inhibitors 157
Combined strategies for the discovery of ionotropic glutamate receptor antagonists 156
3D pharmacophore model and the synthesis of NMDA receptor subunit NR2B antagonists 156
Identification of 3,4-Dihydroisoquinoline-2(1H)-sulfonamides as Potent Carbonic Anhydrase Inhibitors: Synthesis, Biological Evaluation, and Enzyme−Ligand X-ray Studies 155
Analysis of Italian regulations on pathways of care for patients in a vegetative or minimally conscious state 153
Nuovi ligandi del recettore NR2B/NMDA a struttura indolica 152
Searching for indole derivatives as potential mushroom tyrosinase inhibitors 152
Binding mode investigation and SAR studies of HIV-1 integrase inhibitors 150
Synthesis and anti-HIV activity of carboxylated and drug-conjugated multi-walled carbon nanotubes 149
From NMDA receptor antagonists to discovery of selective σ2 receptor ligands 149
Synthesis of new pyridazine derivatives as potential anti-HIV-1 agents 148
Synthesis and structure-active relationship of 1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline anticonvulsants 148
PROGETTAZIONE E SINTESI DI NUOVI DKA ANALOGHI COME POTENZIALI INIBITORI DELL’INTEGRASI DELL’HIV-1 146
Antiretroviral strategy: design and synthesis of HIV-1 IN-LEDGF/p75 interaction inhibitors 146
Small Molecules Targeting Protein–Protein Interactions: A Promising Anti-HIV Strategy 146
Probing the molecular interactions between the human Carbonic Anhydrases (hCAs) and a novel class of benzenesulfonamides 143
Serendipitous discovery of indole derivatives as potent tyrosinase inhibitors 142
Design e Sintesi di composti a struttura 3-Indol-Gliossilamidica come potenziali inibitori dell'integrasi dell'HIV-1. 140
PROGETTAZIONE E SINTESI DI NUOVI DKA ANALOGHI COME POTENZIALI INIBITORI DELL'INTEGRASI DELL'HIV-1 139
Discovery of potent HIV-1 integrase strand transfer inhibitors: design and synthetic strategies 139
Discovery of HIV-1 Integrase and cellular cofactor LEDGF/p75 interaction inhibitors 138
Discovery and optimization of isoquinoline-derived inhibitors of human Carbonic Anhydrases (hCAs) 138
Computational Studies to Discover a New NR2B/NMDA Receptor Antagonist and Evaluation of Pharmacological Profile 137
HIV-1 integrase strand-transfer inhibitors: design and synthetic strategies in the process of a lead optimization 137
Computational and synthetic approaches for the discovery of HIV-1 integrase inhibitors 136
Derivati benzimidazolonici ed analoghi come potenti inibitori non-nucleosidici dell'RT dell'HIV-1 136
Synthesis and SAR of new 1,3-dihydro-benzimidazolone analogues as non-nucleoside reverse transcriptase inhibitors (NNRTIs) 135
PROGETTAZIONE E SINTESI DI NUOVI DERIVATI ISOCHINOLINICI COME AGENTI ANTICONVULSIVANTI MULTITARGET 135
Design, Synthesis and SAR of New Potent HIV-1 RT Inhibitors”. Antiviral Research 135
A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series 134
Insight into the INSTIs binding mode: molecular modeling investigation and SAR studies 134
Synthesis and evaluation of pharmacological profile of 1-aryl-6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-sulfonamides. 134
NOVEL N1-ARYL-2- ARYLTHIOACETAMIDOBENZIMIDAZOLES WERE EFFECTIVE AGAINST HERPES SIMPLEX VIRUS 1 (HSV-1) REPLICATION IN VITRO 134
Computational studies and synthetic approaches for the identification of new protein-protein interaction inhibitors (PPI) 133
Structural optimization of N1-aryl-benzimidazoles for the discovery of new non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains 133
Novel targets for HIV therapy: small molecules blocking IN-LEDGF/p75 interaction 132
New indole derivatives as promising ligands for ifenprodil site of NR2B/NMDA receptors 132
Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase 132
Progettazione, Sintesi e SAR di analoghi 1,3-diidro-benzimidazoloni come nuovi agenti anti-HIV 131
Synthesis, Structure-Activity Relationship Studies, and X-ray Crystallographic Analysis of Arylsulfonamides as Potent Carbonic Anhydrase Inhibitors. 131
Probing Molecular Interactions between Human Carbonic Anhydrases (hCAs) and a Novel Class of Benzenesulfonamides 131
Nuovi Antagonisti Non-Competitivi Del Recettore NMDA/NR2b: Design e Sintesi” 130
Searching for novel N1-substituted benzimidazol-2-ones as non-nucleoside HIV-1 RT inhibitors 130
Identification of potent carbonic anhydrase inhibitors: synthesis, biological evaluation and enzyme-ligand x-ray studies 129
Computational and synthetic approaches for the discovery of HIV-1 integrase inhibitors 128
INTEGRASE STRAND TRANSFER INHIBITORS (INSTIs): SYNTHESIS AND ANTIVIRAL EFFETCS OF CHLORO-FLUORO SUBSTITUTIONS 128
New potent and selective carbonic anhydrase inhibitors: synthesis, biological evaluation and X-ray studies 127
Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists 127
Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors 125
Sintesi e SAR di nuovi inibitori dell'acetilcolinesterasi come potenziali agenti anti-Alzheimer 125
Design, synthesis and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents 125
Design, Synthesis and Biostructural Characterization of Carbonic Anhydrase Inhibitors 125
Indole derivatives as dual-effective agents for the treatment of neurodegenerative diseases: Synthesis, biological evaluation, and molecular modeling studies 123
Structure-based screening for the discovery of new carbonic anhydrase VII inhibitors 123
Synthesis of new potential HIV-1 integrase inhibitors 122
Synthesis and biological characterization of novel potent arylsulfonamides as human carbonic anhydrase inhibitors (hCAIs) targeting central nervous system 122
Rational design, synthesis and evaluation of coumarin derivatives as protein-protein interaction inhibitors 122
Identification of 3-substituted-1H-indoles as ligands of GluN2B containing N-methyl-D-aspartate receptors 121
Searching for NR2B/NMDA Receptor Antagonists As Neuroprotective Agents 120
Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors. 120
Synthesis and biological profile of new 1,2,3,4-tetrahydroisoquinolines as selective carbonic anhydrase inhibitors 120
Simulated human digestion of N1-aryl-2-arylthioacetamidobenzimidazoles and their activity against Herpes-simplex virus 1 in vitro 120
Combined strategies for the discovery of ionotropic glutamate receptor antagonists 119
HIV-1-IN Strand-Transfer Inhibitors: phenyl ring exploration and synthesis of 1H-benzylindole derivative through fluorine substitutions 117
Synthesis, biological evaluation and docking studies of NR2B/NMDA receptor antagonists 114
ISOQUINOLINE-SULFONAMIDES AS A CLASS OF POTENT AND SELECTIVE CARBONIC ANHYDRASE INHIBITORS 111
Identification of influenza PA-Nter endonuclease inhibitors using pharmacophore- and docking-based virtual screening 110
Progettazione razionale e "green" sintesi di nuovi inibitori dell'integrasi dell'HIV-1 107
HIV-1 integrase strand transfer inhibitors (INSTIs): design, synthesis and biological activity 107
N-Substituted Isoquinoline Derivatives as Potential AChE Inhibitors 107
Totale 19.087
Categoria #
all - tutte 68.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.401


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021419 0 0 0 0 0 0 0 0 0 142 85 192
2021/20221.060 10 161 25 48 38 11 81 39 28 11 258 350
2022/20232.901 242 254 143 218 212 297 54 148 1.232 8 74 19
2023/2024682 57 102 50 134 56 124 7 16 1 56 14 65
2024/20253.163 59 46 59 181 109 123 53 728 804 185 277 539
2025/202613.660 363 1.970 3.725 886 780 2.210 1.070 1.224 1.145 287 0 0
Totale 24.983